Eosinophilic Esophagitis (EoE) – Market Access and Reimbursement Insights Report – 2025

Eosinophilic Esophagitis (EoE) Market Access and Reimbursement Insights

Thelansis’s “Eosinophilic Esophagitis (EoE) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.

Eosinophilic Esophagitis (EoE) Overview

Eosinophilic Esophagitis (EoE), often described as the “asthma of the esophagus,” is a chronic, immune‑driven allergic condition marked by dense eosinophil infiltration of the esophageal lining, which causes ongoing inflammation and progressive impairment of esophageal structure and function. The clinical presentation varies with age: in adults, the most common symptoms include dysphagia, food impaction, chest discomfort, and heartburn, whereas in children it more frequently manifests as vomiting, abdominal pain, regurgitation, and feeding difficulties, with swallowing problems and food blockages becoming increasingly evident during adolescence. Diagnosis requires endoscopic biopsy demonstrating ≥15 eosinophils per high‑power field in the esophagus, with exclusion of eosinophilic involvement in the stomach or duodenum. The condition is strongly associated with atopy, as up to three‑quarters of patients have a personal or family history of asthma, eczema, allergic rhinitis, or food/environmental allergies. Unlike gastroesophageal reflux disease, EoE typically does not respond to acid‑suppression therapy, and management relies on dietary elimination of allergens, swallowed topical corticosteroids, and endoscopic dilation for strictures, with long‑term monitoring needed to prevent complications.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.

*Survey and interview discussion guide are customized based on client requirements

Deliverables format:

• PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

• Market access and reimbursement for current therapies
• Coverage on plans
• Market access restrictions
• Rebates and contracting
• Factors influencing formulary access
• HEOR requirements and influence, etc.
• Expected market access and reimbursement for key emerging therapies
• Level of awareness
• Anticipated coverage on plans
• Factors that would improve market access
• Pricing, etc.
• Impact on brand use
• Key factors driving and limiting brand use
• Best and worst performers on market access, etc.
• Evolving environment
• Payer expectations from emerging therapies
• New policies and their expected impact, etc.
• Advise to drug manufacturers and developers

Read more: Eosinophilic Esophagitis (EoE) – Market Access and Reimbursement Insights Report – 2025